[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scienture Holdings Inc (SCNX)

Scienture Holdings Inc (SCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,354
  • Shares Outstanding, K 40,631
  • Annual Sales, $ 430 K
  • Annual Income, $ -41,510 K
  • EBIT $ -43 M
  • EBITDA $ -39 M
  • 60-Month Beta 3.29
  • Price/Sales 35.32
  • Price/Cash Flow N/A
  • Price/Book 0.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.51
  • Most Recent Earnings $-0.08 on 05/15/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3102 +21.82%
on 06/08/26
0.4451 -15.10%
on 05/14/26
-0.0200 (-5.03%)
since 05/12/26
3-Month
0.2382 +58.65%
on 03/30/26
0.5533 -31.70%
on 03/13/26
-0.1326 (-25.97%)
since 03/12/26
52-Week
0.2382 +58.65%
on 03/30/26
2.6000 -85.47%
on 10/23/25
-0.7371 (-66.11%)
since 06/12/25

Most Recent Stories

More News
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market U.S. naloxone market totals ~$144 million in annual sales...

SCNX : 0.3779 (+0.64%)
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...

SCNX : 0.3779 (+0.64%)
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing...

SCNX : 0.3779 (+0.64%)
Scienture Holdings: Q1 Earnings Snapshot

Scienture Holdings: Q1 Earnings Snapshot

SCNX : 0.3779 (+0.64%)
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment Financing...

SCNX : 0.3779 (+0.64%)
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI ™ as the first FDA-approved ready-to-use oral suspension ...

SCNX : 0.3779 (+0.64%)
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing...

SCNX : 0.3779 (+0.64%)
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead

COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing...

SCNX : 0.3779 (+0.64%)
Scienture Holdings: Q4 Earnings Snapshot

Scienture Holdings: Q4 Earnings Snapshot

SCNX : 0.3779 (+0.64%)
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company...

SCNX : 0.3779 (+0.64%)

Business Summary

Scienture Holdings Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs....

See More

Key Turning Points

3rd Resistance Point 0.4273
2nd Resistance Point 0.4096
1st Resistance Point 0.3937
Last Price 0.3779
1st Support Level 0.3601
2nd Support Level 0.3424
3rd Support Level 0.3265

See More

52-Week High 2.6000
Fibonacci 61.8% 1.6978
Fibonacci 50% 1.4191
Fibonacci 38.2% 1.1404
Last Price 0.3779
52-Week Low 0.2382

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.